Englander Institute for Precision Medicine

Molecular determinants of immunogenic cell death elicited by radiation therapy.

TitleMolecular determinants of immunogenic cell death elicited by radiation therapy.
Publication TypeJournal Article
Year of Publication2024
AuthorsGalassi C, Klapp V, Yamazaki T, Galluzzi L
JournalImmunol Rev
Volume321
Issue1
Pagination20-32
Date Published2024 Jan
ISSN1600-065X
KeywordsAdaptive Immunity, Antineoplastic Agents, Cell Death, Humans, Immunogenic Cell Death, Neoplasms, Tumor Microenvironment
Abstract

Cancer cells undergoing immunogenic cell death (ICD) can initiate adaptive immune responses against dead cell-associated antigens, provided that (1) said antigens are not perfectly covered by central tolerance (antigenicity), (2) cell death occurs along with the emission of immunostimulatory cytokines and damage-associated molecular patterns (DAMPs) that actively engage immune effector mechanisms (adjuvanticity), and (3) the microenvironment of dying cells is permissive for the initiation of adaptive immunity. Finally, ICD-driven immune responses can only operate and exert cytotoxic effector functions if the microenvironment of target cancer cells enables immune cell infiltration and activity. Multiple forms of radiation, including non-ionizing (ultraviolet) and ionizing radiation, elicit bona fide ICD as they increase both the antigenicity and adjuvanticity of dying cancer cells. Here, we review the molecular determinants of ICD as elicited by radiation as we critically discuss strategies to reinforce the immunogenicity of cancer cells succumbing to clinically available radiation strategies.

DOI10.1111/imr.13271
Alternate JournalImmunol Rev
PubMed ID37679959
Grant ListPRIDE19/14254520/i2TRON / / Luxembourg National Research Fund (FNR) /
/ / Rapid Response Grant from the Functional Genomics Initiative (New York, US) /
#W81XWH2120034 / / Transformative Breast Cancer Consortium Grant from the US DoD BCRP /
#ZP-6177 / / 2019 Laura Ziskin Prize in Translational Research from the Stand Up to Cancer (SU2C) /
/ / A Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society (LLS) /
AICF; #223565- 01 / / American Italian Cancer Foundation /
/ / Industrial collaborations with Lytix Biopharma (Oslo, Norway), Promontory (New York, US) and Onxeo (Paris, France) /
/ / Pre-SPORE grant (PI: Demaria, Formenti) and a Clinical Trials Innovation Grant from the Sandra and Edward Meyer Cancer Center (New York, US) /
/ / Promontory (New York, US), the Luke Heller TECPR2 Foundation (Boston, US), Sotio a.s. (Prague, Czech Republic), Lytix Biopharma (Oslo, Norway), Onxeo (Paris, France), Ricerchiamo (Brescia, Italy), and Noxopharm (Chatswood, Australia). /
#CA271915 / / R01 grant from the NIH/NCI by two Breakthrough Level 2 grants from the US DoD BCRP /
#BC180476P1 / / R01 grant from the NIH/NCI by two Breakthrough Level 2 grants from the US DoD BCRP /
#BC210945 / / R01 grant from the NIH/NCI by two Breakthrough Level 2 grants from the US DoD BCRP /
#I16-0064 / / STARR Cancer Consortium /
/ / Startup funds from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US) /
#CA274291 / / U54 grant (PI: Formenti, Weichselbaum, Deasy) from NIH/NCI /

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021